[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615850":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":73,"collaborators":77,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":24,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":24,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":46,"whyStopped":24,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Universiti Sains Malaysia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic","EXPERIMENTAL","Daily 2 × 10 9 CFU per 6 drops containing Lactobacillus rhamnosus CRL1505+Bifidobacterium brevis M-16V strain in MCT oil",[13],"Dietary Supplement: Probiotic",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Daily 6 drops of MCT oil without probiotic",[19],"Dietary Supplement: Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT",[9],null,{"type":22,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Daily 6 drops MCT oil without probiotics",[15],[29],{"name":30,"affiliation":31,"role":32},"Sitao Li, MD.","The Sixth Affiliated Hospital of Sun Yat-sen University, Xinyi People's Hospital","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Min-Tze Liong, Ph.D.","CONTACT","6046532114","mintze.liong@usm.my",{"name":40,"role":36,"phone":41,"phoneExt":24,"email":42},"Jie Yuan, M.Sc.","822137027899","peanut.yuan@diprobio.com",[44,56],{"facility":45,"status":46,"city":47,"state":48,"zip":24,"country":49,"countryCode":50,"cosmosGeoPoint":24,"geoPoint":24,"contacts":51},"Xinyi City People's Hospital","RECRUITING","Xingyi","Guangdong","China","CN",[52,55],{"name":30,"role":36,"phone":53,"phoneExt":24,"email":54},"+86 135 7055 0735","lisit@mail.sysu.edu.cn",{"name":40,"role":36,"phone":41,"phoneExt":24,"email":42},{"facility":5,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"NOT_YET_RECRUITING","George Town","Pulau Pinang","11800","Malaysia","MY",{"type":64,"coordinates":65},"Point",[66,67],100.33543,5.41123,{"lat":67,"lon":66},[70,72],{"name":71,"role":36,"phone":37,"phoneExt":24,"email":38},"Min Tze Liong, Ph.D.",{"name":40,"role":36,"phone":41,"phoneExt":24,"email":42},{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Min-Tze LIONG","Prof.",[78],{"name":45,"class":79},"UNKNOWN","100615850","phase-2-evaluation-of-the-clinical-efficacy-of-antrrix-probiotics-in-improving-recurrent-respiratory-infections-in-infants-and-young-children-100615850",false,"NCT07297966","Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children","Inclusion Criteria:\n\n* Age \\\u003C 6 years, gender not limited;\n* Meets the clinical diagnostic criteria for recurrent respiratory tract infections (Clinical Diagnosis and Treatment Pathway for Recurrent Respiratory Tract Infections in Children (2022 Edition) 10 );\n* Parents or other legal guardians of the child fully understand the trial and voluntarily sign informed consent forms before the start of any research procedure;\n* Willing to discontinue the use of other probiotics during the trial;\n* Agree to the collection of fecal biological samples during this trial.\n\nExclusion Criteria:\n\n* Those deemed by the investigator to have poor compliance or be unsuitable for participation;\n* Allergic to the investigational product and its components;\n* Allergic to respiratory tract infection drugs and their components;\n* Respiratory infections caused by underlying diseases such as primary immunodeficiency diseases, acquired immunodeficiency syndrome (ADRS), congenital airway malformations, congenital heart disease, gastroesophageal reflux disease (GERD), and pulmonary dysplasia;\n* Patients with severe malnutrition, rickets, and severe primary diseases of the heart, brain, liver, kidney, and hematopoietic systems;\n* Use probiotic preparations, antibiotics, immunostimulants, or immunosuppressants 4 weeks before participating in the experiment.","ALL","1 Day","6 Years",{"count":90,"type":91},120,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","This study is an 8-weeks, randomized controlled trial involving children under 6 years of age who meet clinical diagnostic criteria for RRTI. Participants are randomized to receive either probiotic or placebo. The primary clinical outcomes assessed are duration and frequency of respiratory symptoms and quality of life. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.",[97],"Recurrent Respiratory Tract Infections",[99,100,101,102],"RRTI","probiotic","RCT","children","2026-04-14",{"date":105,"type":106},"2026-04-17","ACTUAL",{"date":108,"type":106},"2025-05-14",{"date":110,"type":91},"2026-06-30",{"name":75,"class":6},2]